Julio Molineros

Janssen Pharmaceuticals
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

Year:

2026

Whole-genome sequencing provides an unbiased and complete view of the human genome and enables the discovery of genetic variation without the technical limitations of other genotyping technologies. Here we report on whole-genome sequencing of 490,640 UK Biobank participants, building on previous genotyping effort 1 . This advance deepens our understanding of how genetics associates with disease biology and further enhances the value of this open resource for the study of human biology and health. Coupling this dataset with rich phenotypic data, we surveyed within- and cross-ancestry genomic associations and identified novel genetic and clinical insights. Although most associations with disease traits were primarily observed in individuals of European ancestries, strong or novel signals were also identified in individuals of African and Asian ancestries. With the improved ability to accurately genotype structural variants and exonic variation in both coding and UTR sequences, we strengthened and revealed novel insights relative to whole-exome sequencing 2,3 analyses. This dataset, representing a large collection of whole-genome sequencing data that is available to the UK Biobank research community, will enable advances of our understanding of the human genome, facilitate the discovery of diagnostics and therapeutics with higher efficacy and improved safety profile, and enable precision medicine strategies with the potential to improve global health.

Year:

2025

Psoriasis is a common autoimmune disease with a strong genetic component. Targeting the IL-23/IL-17 pathways for the treatment of moderate-severe psoriasis has proven successful, which makes it a good benchmark for other drug discovery approaches. Genome Wide Association Studies (GWAS) identify genetic loci associated with a phenotype (e.g. disease). However, using identified loci to understand the disease mechanisms remains challenging. In response, gene networks methods that consider gene-gene relationships have been developed. In a previous study, we showed that the combination of network methods improved the power, reproducibility, and interpretability of those approaches on a small cohort of breast cancer patients. The goal of the present study is to benchmark the performance of the same combination of network methods on a psoriasis cohort from the UK biobank (with a particular interest on the IL-23/IL-17 pathways). By applying this method, we identified well known psoriasis genes, demonstrating the viability of our approach. Our method further identified a small set of genes of the MRPL family robustly associated with psoriasis, demonstrating that this approach can provide insights into the potential disease mechanisms. Our study also shows that our method is applicable to large-scale biobank data to produce novel findings, even in well-studied diseases with strong genetic signal.

Year:

2025

Collaborators (5)

Florian Massip

-

FRANCE
View details

Chloé-Agathe Azencott

Professor

Mines ParisTech

FRANCE
View details

Lauren Carson

Head of Research Development

-

UNITED KINGDOM
View details

David Jackson

Wellcome Sanger Institute

UNITED KINGDOM
View details

Peter Maccallum

Chief Technical Officer

ELRIG

UNITED KINGDOM
View details